Citius Pharmaceuticals (NASDAQ:CTXR) Sets New 52-Week Low – What’s Next?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) shares hit a new 52-week low on Tuesday . The stock traded as low as $2.55 and last traded at $3.36, with a volume of 1113436 shares. The stock had previously closed at $3.34.

Wall Street Analyst Weigh In

Several brokerages have weighed in on CTXR. D. Boral Capital restated a “hold” rating on shares of Citius Pharmaceuticals in a research report on Friday, November 22nd. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Citius Pharmaceuticals in a research report on Tuesday, November 12th.

Citius Pharmaceuticals Price Performance

The firm’s 50-day simple moving average is $9.35 and its two-hundred day simple moving average is $14.20. The company has a market capitalization of $650.61 million, a price-to-earnings ratio of -15.00 and a beta of 1.66.

Institutional Trading of Citius Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Miller Investment Management LP lifted its holdings in shares of Citius Pharmaceuticals by 99.3% in the third quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock valued at $50,000 after purchasing an additional 49,640 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Citius Pharmaceuticals in the second quarter valued at about $29,000. Arkadios Wealth Advisors lifted its holdings in shares of Citius Pharmaceuticals by 33.3% in the third quarter. Arkadios Wealth Advisors now owns 200,000 shares of the company’s stock valued at $100,000 after purchasing an additional 50,000 shares in the last quarter. Wealth Advisory Solutions LLC lifted its holdings in shares of Citius Pharmaceuticals by 33.1% in the third quarter. Wealth Advisory Solutions LLC now owns 201,000 shares of the company’s stock valued at $101,000 after purchasing an additional 50,000 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of Citius Pharmaceuticals in the third quarter valued at about $47,000. Hedge funds and other institutional investors own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.